Low-Dose Therapy With the Long-Acting Erythropoietin Analogue Darbepoetin Alpha Persistently Activates Endothelial Akt and Attenuates Progressive Organ Failure

Ferdinand H. Bahlmann, MD*; Rong Song, MD*; Sascha M. Boehm, MS; Michael Mengel, MD; Reinhard von Wasielewski, MD; Carsten Lindschau, PhD; Torsten Kirsch, PhD; Kirsten de Groot, MD; Robert Laudeley, BS; Eva Niemczyk, BS; Faikah Güler, MD; Jan Menne, MD; Hermann Haller, MD; Danilo Fliser, MD

Background—The hematopoietic cytokine erythropoietin has cytoprotective effects in endothelial cells in vitro that are mediated through direct activation of the pro-survival Akt tyrosine kinase signaling pathway. We tested the hypothesis that low-dose therapy with the long-acting recombinant human erythropoietin analogue darbepoetin alpha protects vascular endothelium in vivo in a classic remnant kidney rat model characterized by severe endothelial damage, progressive vascular sclerosis, and ischemia-induced tissue fibrosis.

Methods and Results—Using a parallel group study design, we randomly assigned animals after 5/6 nephrectomy to treatment with either saline (n=36) or 0.1 μg/kg body wt darbepoetin (n=24) subcutaneously once weekly. We monitored hematocrit, blood pressure, and serum creatinine regularly and obtained renal tissue 6 weeks after nephrectomy for morphological and immunohistochemical analysis. Darbepoetin-treated animals had significantly improved survival compared with saline-treated controls (63% versus 33%; P<0.05), although hematocrit levels were similar in both groups. Darbepoetin treatment ameliorated endothelial damage; attenuated the composite tissue injury score (saline 1.9±0.4; darbepoetin 0.4±0.2; P<0.001), which included vascular sclerosis, glomerulosclerosis, and tubulointerstitial damage; and preserved renal function. We found persistent activation of the pro-survival Akt signaling pathway in endothelial and epithelial glomerular cells in darbepoetin-treated animals, accompanied by a significant reduction of apoptotic cell death in renal tissue.

Conclusions—Low-dose darbepoetin treatment confers vascular and tissue protection that is associated with persistent stimulation of the pro-survival Akt signaling pathway. The use of recombinant human erythropoietin or analogues may have utility in preventing ischemia-related progressive vascular injury and organ failure. (Circulation. 2004;110:1006-1012.)

Key Words: apoptosis ■ erythropoietin ■ tissue ■ vasculature ■ endothelium

Recent experimental studies on the progression of chronic renal diseases have revealed that the process features progressive glomerular capillary sclerosis, loss of peritubular capillaries, and ischemia-induced tubulointerstitial fibrosis.1,2 The integrity of the endothelium forming the glomerular capillary tufts and the peritubular capillaries is vital for the preservation of renal function, and proangiogenic growth factors such as vascular endothelial growth factor (VEGF) play a central role in maintaining renal morphology and function after injury.3,4

Another proangiogenic growth factor currently receiving attention in cardiovascular research is the hematopoietic cytokine erythropoietin (EPO). EPO has pleiotropic effects well beyond the maintenance of red blood cell mass.5–7 In the embryo, EPO is a major regulator of vascular formation and organ growth; EPO receptors are found in almost every embryonic tissue.8 EPO receptors also exist in many adult tissues, and the notion of autocrine or paracrine EPO systems has been raised.5,9–11 EPO also acts on endothelial cells.12,13 Human endothelial cells respond to EPO by differentiating into vascular structures.14,15 In addition, EPO has important cytoprotective effects, including protection from ischemic injury and inhibition of apoptotic death–related pathways.16,17 We speculated that EPO might preserve its role as an endothelial cell regulator to preserve or even repair capillaries in the adult organism.18 To test this possibility, we studied

Received December 16, 2003; de novo received February 26, 2004; revision received May 13, 2004; accepted May 19, 2004.

From the Division of Nephrology, Department of Internal Medicine (F.H.B., R.S., S.M.B., C.L., T.K., K.d.G., F.G., H.H., D.F.), and Institute of Pathology (M.M., R.v.W.), Hannover Medical School; and Phenos GmbH (R.L., E.N., J.M.), Hannover, Germany.

*The first 2 authors contributed equally to this work.

Correspondence to Ferdinand H. Bahlmann, MD, Department of Internal Medicine, Hannover Medical School, Carl-Neuberg Strasse 1, 30625 Hannover, Germany. E-mail Bahlmann.Ferdinand@MH-Hannover.de

© 2004 American Heart Association, Inc.

Circulation is available at http://www.circulationaha.org DOI: 10.1161/01.CIR.0000139335.04152.F3

1006
chronic renal disease progression in the established 5/6 nephrectomy rat remnant kidney (RK) model. The model features progressive injury to the renal microvascular endothelium, leading to glomerular sclerosis accompanied by ischemia-induced tubulointerstitial damage. The course of the disease is inexorable and leads to death. We chose low-dose treatment with the long-acting recombinant human EPO (rHuEPO) analogue darbepoetin alpha because we recently found that darbepoetin stimulates human bone marrow–derived endothelial progenitor cells at doses that do not increase the hematocrit level. An increased hematocrit level could possibly contribute to elevated blood pressure and/or vascular thrombosis.

Methods

Studies on Survival After Induction of 5/6 Nephrectomy

The Animal Care Committee of Lower Saxony approved the study. We measured baseline blood pressure and renal function in 60 male Sprague-Dawley rats (Charles River Wiga GmbH, Sutzfled, Germany) weighing between 250 and 300 g by a tail-cuff method. We performed selective ligation of the extrarenal arterial branches of the left renal artery under ketamine and xylazine anesthesia to obtain a two-thirds renal infarction. The opposite kidney was then removed. We used a parallel group study design, and all animals were randomly assigned to receive either saline (0.9% NaCl) or 0.1 μg/kg body wt darbepoetin alpha (Aranesp, Amgen Co) subcutaneously once weekly after 5/6 nephrectomy starting after surgery. Animals were randomized in a 3:2 manner to saline (n = 12) or darbepoetin alpha (n = 24). We chose this protocol because in a pilot study exploring the effect of darbepoetin on hematocrit levels in RK rats, we observed fewer deaths in darbepoetin-treated RK animals than in saline-treated animals. All animals had free access to water and were given standard chow. We measured body weight and hematocrit before nephrectomy and weekly thereafter. Systolic blood pressure was measured in conscious animals with the use of an occlusive tail-cuff plethysmograph attached to a pneumatic pulse transducer (TSE blood pressure system); for the measurements we kept animals under ketamine anesthesia. We then removed the left renal artery under ketamine and xylazine anesthesia to obtain a two-thirds renal infarction. The opposite kidney was then removed. We used a parallel group study design, and all animals were randomly assigned to receive either saline (0.9% NaCl) or 0.1 μg/kg body wt darbepoetin alpha (Aranesp, Amgen Co) subcutaneously once weekly after 5/6 nephrectomy starting after surgery. Animals were randomized in a 3:2 manner to saline (n = 36) or darbepoetin (n = 24). We chose this protocol because in a pilot study exploring the effect of darbepoetin on hematocrit levels in RK rats, we observed fewer deaths in darbepoetin-treated RK animals than in saline-treated animals. All animals had free access to water and were given standard chow. We measured body weight and hematocrit before nephrectomy and weekly thereafter. Systolic blood pressure was measured in conscious animals with the use of an occlusive tail-cuff plethysmograph attached to a pneumatic pulse transducer (TSE blood pressure system); for the measurements we kept animals under ketamine anesthesia.

Statistical Analysis

We used the SPSS package (SPSS 11.51 for Windows). We analyzed survival with a log-rank analysis and created Kaplan-Meier survival curves. In addition, we compared baseline and end point characteristics with ANOVA and appropriately corrected t tests for random data. We analyzed data on the time course of Akt activation and apoptosis with ANOVA and appropriately corrected t tests. Differences were considered significant at \( P < 0.05 \). Data are mean ± SEM unless otherwise stated.

Results

Animal Survival

Fifteen of 24 darbepoetin-treated RK rats (63%) survived 6 weeks, compared with 12 of 36 saline-treated RK controls (33%) \( (P < 0.05) \). The Kaplan-Meier survival curve is shown in Figure 1. Both serum creatinine concentrations and urinary protein excretion in saline-treated RK rats increased significantly during the observation period and were significantly higher at 6 weeks compared with darbepoetin-treated RK animals (Table). Systolic blood pressure in saline-treated RK animals increased markedly, whereas in darbepoetin-treated RK animals systolic blood pressure was slightly but not significantly higher at 6 weeks than at baseline (Table). Hematocrit levels in both groups increased slightly postoperatively, probably because of reduced water and food intake. Thereafter, hematocrit levels decreased steadily, as shown in
Figure 2. The hematocrit levels were not different between the groups.

Renal Morphology
Photomicrographs of the histopathology are presented in Figure 3. Severe vascular and glomerular damage occurred in saline-treated RK rats. Onionlike vascular wall proliferation occurred in larger renal vessels, reminiscent of human malignant nephrosclerosis. Partial or complete glomerulosclerosis with hyalinosis and fibrinoid necrosis of the adjacent afferent arterioles were prominent features. Furthermore, as shown in Figure 4, focal rarefaction of peritubular capillaries was present. The vascular changes were accompanied by tubulointerstitial inflammation and fibrosis. All these typical RK model changes were attenuated with darbepoetin treatment. The composite tissue injury score that encompassed vascular sclerosis, glomerulosclerosis, and tubulointerstitial damage was significantly reduced in darbepoetin-treated RK rats compared with saline-treated RK rats (0.4 ± 0.2 versus 1.9 ± 0.4; P < 0.001). In addition, rarefaction of peritubular capillaries was prevented by darbepoetin treatment (Figure 4).

Renal Immunohistology
Renal tissue staining for activated Akt (p-Akt [Ser473]) is shown in Figure 5. We found activation of the Akt pathway in glomerular endothelial cells and epithelial cells at day 4 after nephrectomy in both treatment groups. Akt activation was more pronounced in darbepoetin-treated animals. After 2 weeks of treatment, marked Akt activation was detectable in tissue of darbepoetin-treated animals, but it remained modest in RK rats treated with saline. In darbepoetin-treated animals surviving 6 weeks after nephrectomy, p-Akt staining in tissue of darbepoetin-treated animals was more pronounced than in saline-treated RK rats (Figure 5). We did not observe differences with respect to HO-1, HSP27, and VEGF expression between the groups (data not shown). Staining for apoptotic cell nuclei (TUNEL) revealed a large increase of apoptotic activity in renal tissue of nephrectomized animals at treatment days 4 and 14 (Figure 6). Apoptosis was significantly reduced in darbepoetin-treated RK rats compared with saline-treated animals. In animals surviving 6 weeks after nephrectomy, we found only low-grade apoptotic activity in renal tissue of both saline- and darbepoetin-treated RK rats.

Discussion
We found that chronic treatment with the long-acting EPO analogue darbepoetin alpha prevented endothelial injury in an experimental model of progressive chronic renal disease. One important feature of renal injury in this particular model is hypertension, which alone perpetuates endothelial activation, inflammation, and proliferation, followed by vascular obliteration and glomerulosclerosis. As a consequence, peritubular capillary disappearance accompanied by ischemia-induced tubulointerstitial fibrosis finally leads to renal failure and to death of the animals. The process involves chemokine...
and cytokine release, adhesion molecule expression, platelet and macrophage infiltration, cell activation, proliferation, matrix protein deposition, and eventually sclerosis and obliteration. Darbepoetin treatment significantly reduced glomerulosclerosis and prevented destruction of arterial integrity, maintaining the peritubular capillary network and the architecture of the renal interstitium, a particularly vulnerable part of the kidney to ischemic injury. Its integrity critically depends on blood flow in peritubular capillaries, which evolve from the efferent arteriole. These effects were accompanied by improved renal function and significantly better survival. The preserved renal function probably contributed to a lesser blood pressure elevation in the darbepoetin-treated animals.

EPO may also protect other organs from various sorts of injury. In a recent study, rHuEPO was given to animals with experimentally induced myocardial ischemia/reperfusion injury.21 Treated animals exhibited improved cardiomyocyte survival and preserved myocardial function. In a similar study, Parsa et al17 performed myocardial preconditioning experiments with a single high dose of rHuEPO in a rabbit model of acute myocardial infarction. Pretreatment with rHuEPO protected cardiomyocytes against ischemic injury, mitigated myocyte apoptosis, and led to improved myocardial function within 3 days after infarction. Both studies were relatively small, and therefore a beneficial effect on survival could not be tested. Because rHuEPO treatment may have adverse effects, improved survival would be an important
In our study, a clear-cut beneficial effect on survival was evident. The effect of rHuEPO on cell and whole organ function has been examined in earlier studies. The rHuEPO doses used in many of these studies were extremely high. For instance, Parsa et al. gave 5000 U/kg body wt in their preconditioning experiment. The dose corresponds to ≈350,000 U in a 70-kg man. Such a dose is not conceivable clinically. RHuEPO overdose may lead to hypertension, seizures, vascular thrombosis, and death, perhaps related to abruptly increased hematocrit values. Parsa et al. reported a 20% increase in hematocrit by day 4 in their rabbit study.

Figure 4. CD31 staining of peritubular capillaries in renal tubulointerstitium of RK rats treated with saline or darbepoetin. The CD31 stain revealed regular peritubular capillary network in darbepoetin-treated animals (left), whereas focal rarefaction of peritubular capillaries was seen in saline-treated rats (right).

Figure 5. Immunohistochemical analysis for Akt phosphorylation (p-Akt [Ser473]) in glomeruli of RK rats treated with saline or darbepoetin. Akt activation was detectable at day 4 after nephrectomy in both treatment groups; it was more pronounced in darbepoetin-treated animals (B and C). After 2 weeks of treatment we found marked Akt activation in darbepoetin-treated animals, whereas in RK rats treated with saline, Akt activation remained modest (D and E). Finally, in darbepoetin-treated animals surviving 6 weeks after nephrectomy, p-Akt staining in glomerular endothelial cells and epithelial cells was prominent, whereas in saline-treated RK rats it was almost absent (F and G). Normal tissue is shown as control (A).
were not involved in our model. Activation of the Akt pathway is a powerful mechanism to protect cells from ischemic injury. VEGF is also an important Akt pathway stimulator. Recently, mesenchymal stem cells genetically enhanced with Akt1 were found to be ischemia resistant. In the heart, the genetically engineered cells prevented cardiac remodeling and restored performance of hearts with infarction, compared with stem cells not overexpressing Akt1. These findings suggest that Akt may have a central role in cell protection from ischemia. Our results in RK rats are in agreement with this assumption. They also support the notion that direct Akt activation is an important mechanism for tissue protection by EPO because we did not observe differences in VEGF expression in renal tissue of saline- and darbepoetin-treated animals. We also investigated the degree of apoptosis in renal tissue of RK rats from both groups. EPO in vitro inhibits apoptotic death–related pathways in some cell lines. We found a large increase of apoptotic activity in renal tissue of nephrectomized animals, and treatment with darbepoetin ameliorated this process. The effect of darbepoetin was particularly evident at day 14 after nephrectomy, ie, when massive endothelial activation and proliferation, followed by vascular obliteration, glomerulonephrosis, and ischemia-induced tubulointerstitial damage take place. In contrast, we found only low-grade apoptotic activity in animals of both groups surviving until week 6. We interpret these findings as evidence that darbepoetin treatment prevented the “first-strike” injury at the endothelial cell level and, in addition, reduced apoptotic cell death and preserved tissue integrity in the critical phase of tissue damage and destruction. These effects may be mediated, at least in part, by a persistent activation of the pro-survival Akt pathway.

In conclusion, chronic low-dose therapy with the long-acting rHuEPO analogue darbepoetin alpha conferred vascular and tissue protection, lowered blood pressure, preserved renal function, and improved survival in the RK rat model. The findings offer experimental and perhaps clinical perspectives. Other animal models of progressive ischemia–related organ failure must be tested, and the entire protective pathway must be elucidated. Conceivably, new clinically relevant therapies could be developed.

Acknowledgments
We thank Johanna Sowa, Melanie Paschy, and Torsten Duckert for their technical assistance. We further thank Professor Friedrich Luft for his magnificent editing of the manuscript.

References


Low-Dose Therapy With the Long-Acting Erythropoietin Analogue Darbepoetin Alpha Persistently Activates Endothelial Akt and Attenuates Progressive Organ Failure
Ferdinand H. Bahlmann, Rong Song, Sascha M. Boehm, Michael Mengel, Reinhard von Wasielewski, Carsten Lindschau, Torsten Kirsch, Kirsten de Groot, Robert Laudeley, Eva Niemczyk, Faikah Güler, Jan Menne, Hermann Haller and Danilo Fliser

*Circulation.* 2004;110:1006-1012; originally published online August 9, 2004;
doi: 10.1161/01.CIR.0000139335.04152.F3
*Circulation* is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2004 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the
World Wide Web at:
http://circ.ahajournals.org/content/110/8/1006

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Circulation* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to *Circulation* is online at:
http://circ.ahajournals.org//subscriptions/